" class="no-js "lang="en-US"> Roger Sawhney - Medtech Alert
Saturday, September 23, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Roger Sawhney

Roger Sawhney

About Roger Sawhney

Specialties: Biopharma and health care investing and operational management, private equity and venture capital, BD&L screening and diligence/ alliance management, R&D portfolio management and commercialization, M&A screening and diligence, post-merger integration

Related Story

Fundraising

 Omega Therapeutics to Advance Pipeline and Platform Development with $126 Million in Additional Financing | Pharmtech Focus

Omega Therapeutics to Advance Pipeline and Platform Development with Additional Financing

March 30 2021

Omega Therapeutics, Inc. (“Omega“), a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to […]